U.S. Economy Grew at 2.1% in First Quarter, Revised Upward From Previous Estimate
The U.S. economy expanded at a 2.1% annualized rate in the first quarter of 2026, according to the Commerce Department’s final GDP estimate, marking a sharper upward revision than previously reported. The figure, released on April 29, 2026, reflects stronger-than-expected business investment and government spending, though consumer spending growth slowed significantly, according to multiple reports.
Revised Growth Outpaces Initial Forecast
The 2.1% growth rate for January-March 2026 represents an upward revision from the initial 1.9% estimate, as businesses and federal agencies reported higher capital expenditures and infrastructure spending, according to the Bureau of Economic Analysis (BEA). This revision underscores a resilient economic foundation despite rising interest rates and inflationary pressures.

“The upward adjustment highlights the durability of the private sector, particularly in manufacturing and technology,” said a BEA spokesperson. “However, the slowdown in consumer spending suggests households are cautiously navigating higher borrowing costs.”
Consumer Spending Stalls as Inflation Eases
Consumer spending, which typically accounts for about 70% of U.S. economic activity, grew at a muted 0.8% pace in Q1 2026, the slowest since mid-2024, per Reuters. This contrasted with the 1.2% growth reported in the initial estimate, as households reduced discretionary purchases amid lingering price pressures.
“The deceleration in consumer demand is a key risk for second-quarter growth,” said Laura Tyson, former chair of the Council of Economic Advisers, in a commentary for Advisor Perspectives. “While inflation has eased, wage growth remains below pre-pandemic trends, leaving households with less room to spend.”
Business Investment Drives Expansion
Business investment in structures and equipment rose 4.3% in Q1 2026, the fastest pace since 2022, according to AP News. This surge was fueled by corporate spending on semiconductors, renewable energy projects, and AI infrastructure, driven by both tax incentives and long-term strategic planning.
The government also contributed to growth, with federal spending increasing 2.7% after a 1.5% decline in the previous quarter. This shift followed the passage of a $1.2 trillion infrastructure bill in late 2025, which allocated funds for transportation and broadband upgrades.
Contrasting Outlets Highlight Divergent Narratives
While Fox Business emphasized the revised GDP figure as a sign of economic resilience, Reuters noted the “near stall” in consumer spending as a potential headwind. The disparity in framing reflects broader debates about whether the recovery is broad-based or reliant on specific sectors.

“The data shows a mixed picture,” said economist Mark Zandi of Moody’s Analytics. “Business investment is a positive, but sustained growth will depend on households regaining confidence.”
What’s Next for the U.S. Economy?
Economists are closely watching the Federal Reserve’s next steps, as policymakers grapple with whether to continue raising rates or pivot toward easing. The Fed’s latest statement, released on April 28, 2026, hinted at a “data-dependent” approach, with officials citing both inflation risks and the need to avoid a recession.
“The key question is whether the current momentum can carry into the second half of the year,” said Joseph Stiglitz, Nobel laureate and Columbia University professor. “A sustained recovery will require more than just business investment—it needs stronger labor market dynamics.”
For now, the revised GDP numbers offer a cautiously optimistic outlook, but the path forward remains uncertain. As businesses and households adjust to evolving economic conditions, the interplay between corporate spending, consumer behavior, and policy decisions will shape the trajectory of the U.S. economy in 2026.
Worth a look
- MOFA Criticized for Hiring Convicted Former Diplomat to Affiliated Agency
- Mark Carney Pitches Canada to Global Investors Amid US Trade Tensions
- Breakthrough Salk Study Uncovers Mechanism Behind Immunotherapy Resistance: Interferons, Mitochondrial Dysfunction, and PGE2″ Interferons, mitochondrial dysfunction and PGE2: Salk study reveals mechanism behind immunotherapy resistance. Boost its search engine visibility with relevant keywords for maximum impact. Immunotherapy resistance remains one of the biggest hurdles in cancer treatment. According to a recent study published in the journal Nature Communications, scientists at the Salk Institute have made a groundbreaking discovery that sheds light on the underlying mechanisms behind this resistance. The study reveals that interferons, a type of protein that plays a crucial role in the immune system, can contribute to mitochondrial dysfunction in cancer cells. This dysfunction can lead to the production of prostaglandin E2 (PGE2), a molecule that promotes tumor growth and resistance to immunotherapy. In their study, the researchers found that PGE2 production was a key factor in the development of immunotherapy resistance in cancer cells. The team used a combination of experimental and computational models to investigate the relationship between interferons, mitochondrial dysfunction, and PGE2 production. The findings of the study suggest that targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance. The researchers propose that blocking PGE2 receptors or inhibiting its production could help restore the function of mitochondria in cancer cells, making them more susceptible to immunotherapy. The study’s authors hope that their findings will pave the way for the development of new therapies that can overcome immunotherapy resistance and improve treatment outcomes for cancer patients. Key Takeaways: – Interferons contribute to mitochondrial dysfunction in cancer cells – Mitochondrial dysfunction leads to PGE2 production, promoting tumor growth and resistance to immunotherapy – Targeting PGE2 production could be a potential strategy for overcoming immunotherapy resistance – Restoring mitochondrial function in cancer cells could make them more susceptible to immunotherapy Keywords: immunotherapy resistance, interferons, mitochondrial dysfunction, PGE2, Salk Institute, cancer treatment, breakthrough study, Nature Communications. (archyworldys.com)